Highview Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Highview Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.85M	Buy	5,745 +171	+3%	+$75.8K	0.82%	36
2026 Q1	$2.49M	Buy	5,574 +165	+3%	+$76.9K	0.9%	29
2025 Q4	$2.45M	Sell	5,409 -294	-5%	-$127K	0.87%	33
2025 Q3	$2.23M	Sell	5,703 -282	-5%	-$118K	0.82%	36
2025 Q2	$2.66M	Buy	5,985 +68	+1%	+$31.3K	1.03%	27
2025 Q1	$2.87M	Buy	5,917 +146	+3%	+$68K	1.2%	26
2024 Q4	$2.32M	Buy	5,771 +102	+2%	+$47.3K	0.89%	32
2024 Q3	$2.64M	Buy	5,669 +134	+2%	+$64.4K	1.07%	27
2024 Q2	$2.59M	Buy	5,535 +110	+2%	+$47.7K	1.08%	26
2024 Q1	$2.27M	Buy	5,425 +346	+7%	+$146K	1.02%	26
2023 Q4	$2.07M	Buy	5,079 +121	+2%	+$44.7K	1.1%	23
2023 Q3	$1.72M	Sell	4,958 -7	-0.1%	-$2.45K	0.99%	26
2023 Q2	$1.75M	Buy	4,965 +239	+5%	+$80.5K	0.94%	28
2023 Q1	$1.49M	Buy	4,726 +26	+0.6%	+$7.8K	0.86%	30
2022 Q4	$1.36M	Buy	4,700 +54	+1%	+$16.5K	0.83%	29
2022 Q3	$1.34M	Buy	+4,646	New	+$1.34M	1%	25

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Highview Capital Management's VRTX Position: Q2 2026 in Review

Highview Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 3.1% in Q2 2026, buying an estimated $75.8K and bringing the position to 5,745 shares worth $2.85M. The position accounts for 0.82% of the portfolio, ranked #36.

Highview Capital Management first reported a position in VRTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.87M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Highview Capital Management held 5,745 shares of Vertex Pharmaceuticals worth $2.85M as of Q2 2026.
Highview Capital Management bought 171 Vertex Pharmaceuticals shares in Q2 2026, an estimated $75.8K.
Vertex Pharmaceuticals made up 0.82% of Highview Capital Management's portfolio in Q2 2026, its #36 holding.
Highview Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Highview Capital Management's Vertex Pharmaceuticals position peaked at $2.87M in Q1 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Highview Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.